Cite
HARVARD Citation
Solem, C. et al. (2020). A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer. 126 (19), pp. 4315-4321. [Online].